Kura Oncology, Inc. (KURA) research
Kura Oncology, Inc.- Sector
- Healthcare
- Industry
- Biotechnology
- Last price
- $10.65
- As of
Kura Oncology, Inc. (KURA): 4 institutional managers tracked by Kresmion reported non-option positions in their 2026Q2 Form 13F filings, and the most recent SEC filing on record for the company is a Form 8-K filed 2026-09-09.
As of . Source: SEC EDGAR filings for KURA. Method and limitations.
Share the KURA intelligence card
See the full KURA dossier
Price with insider and filing markers, who is positioning, fundamentals and peers for KURA on one page. Preview it with sample data, then open it live with a free account.
Preview the KURA dossierActive signals for KURA
- highINSTITUTIONAL_EXIT
MILLENNIUM MANAGEMENT LLC cut 55% of KURA (2026Q2)
- highINSTITUTIONAL_SURGE
CITADEL ADVISORS LLC added +276% to KURA (2026Q2)
- highINSTITUTIONAL_EXIT
TWO SIGMA INVESTMENTS, LP cut 53% of KURA (2026Q2)
- mediumEARNINGS_BEAT
Q2-2026: Beat consensus by 14.0%, EPS $-0.77 vs $-0.8952 estimate
- mediumEARNINGS_MISS
Q2-2025: Missed consensus by 60.2% - EPS $-0.75 vs $-0.4681 estimate
FREE, NO ACCOUNT
Every signal on KURA, as it fires
You are seeing 5 of 7 signals recorded on KURA since 2026-05-31.
The five above landed across 3 days. The other 2 were recorded on those same days.
No fixed schedule: it goes out when the data has something in it. Unsubscribe anytime. We never sell your data.
Largest reported share positions in KURA (2026Q2)
| Manager / security | Market value | % portfolio | QoQ |
|---|---|---|---|
| RENAISSANCE TECHNOLOGIES LLCCUSIP 50127T109 · 2026Q2 | $18.3M | 0.03% | , |
| MILLENNIUM MANAGEMENT LLCCUSIP 50127T109 · 2026Q2 | $7.8M | 0.00% | , |
| CITADEL ADVISORS LLCCUSIP 50127T109 · 2026Q2 | $3.6M | 0.00% | , |
| TWO SIGMA INVESTMENTS, LPCUSIP 50127T109 · 2026Q2 | $1.8M | 0.00% | , |
Quarterly SEC Form 13F disclosures from the managers Kresmion tracks, not a complete ownership ranking. Non-option holdings only; reported put and call positions are excluded. Different securities are labeled by CUSIP. Values are reporting-period snapshots, not current position values. Filings can arrive up to 45 days after quarter-end.
Recent SEC filings, KURA
- 8-KSEC EDGAR ↗
- 8-KSEC EDGAR ↗
- 8-KSEC EDGAR ↗
- 10-QSEC EDGAR ↗
- 8-KSEC EDGAR ↗
- 8-KSEC EDGAR ↗
- 8-KSEC EDGAR ↗
- 10-QSEC EDGAR ↗
- 8-KSEC EDGAR ↗
- 10-KSEC EDGAR ↗
KURA against its peers
KURA's operating margin of -449.9% ranks in the 15th percentile of 9 Biotechnology sub-industry peers, fiscal period ending 2025-12-31.
| Metric | KURA | Peer median | Percentile | n |
|---|---|---|---|---|
| Revenue FY | 67.5M USD | 107M USD | 35 | 9 |
| Operating margin | -449.9% | -43.8% | 15 | 9 |
| Net margin | -412.9% | -31.2% | 15 | 9 |
| Return on equity | -160.0% | -38.3% | 4 | 13 |
Peers (16): ABUS, CRVS, CGEM, MLTX, JBIO, GLUE, RIGL, TBPH, ARDX, JANX, SANA, SGP, SVRA, LXRX, MGTX, MNKD. Left out: APMD (no annual filing), ANL (period gap), IVA (period gap), ODTX (no annual filing), HELP (period gap), SPTX (no annual filing), AKTS (no annual filing), SLBT (no annual filing), OBX (no annual filing). Fiscal period ending 2025-12-31. Every figure is one full fiscal year read from one annual filing (KURA: 10-K), reported in USD. Nothing is trailing twelve months and nothing is converted between currencies. Source: SEC EDGAR XBRL company facts (public domain); prices from Kresmion's daily equity market-data snapshot. Open the full comparison.
Related tickers
See more KURA signals as they fire
Kresmion publishes filings, 13F flows, on-chain whale activity, and cross-asset signals in real time. Open a live board scoped to KURAand get the insider, 13F, options, and confluence read in one view.